SCHEMBL19914934

SCHEMBL19914934

CC(C)(C)c1ccc(CN2CCNCC2)c(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.49
DDR1 Q08345 4/20 0.46
MELK Q14680 2/20 0.43
CSF1R P07333 1/20 0.43
YES1 P07947 1/20 0.43
RET P07949 1/20 0.43
FGFR1 P11362 1/20 0.43
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
FLT3 P36888 1/20 0.43
NTRK2 Q16620 1/20 0.43
DDR2 Q16832 1/20 0.43
TACR1 P25103 1/20 0.43
LMNA P02545 1/20 0.42
MKNK1 Q9BUB5 4/20 0.42
MKNK2 Q9HBH9 4/20 0.42
ABL1 P00519 2/20 0.42
CYP3A4 P08684 2/20 0.42
BCR P11274 2/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19911117 0.86 NR1H2 (0.51) NR1H2DDR1KDM4EALDH1A1ATM
SCHEMBL19911119 0.84 NR1H2 (0.53) NR1H2RETFLT3MKNK1MKNK2
SCHEMBL9609582 0.84 NR1H2 (0.68) NR1H2DDR1ABL1KDM4EALDH1A1
SCHEMBL15237068 0.83 PDE3B (0.50) NR1H2KDM4EALDH1A1ATMTSHR
SCHEMBL9609583 0.83 MLNR (0.48) NR1H2TACR1ABL1ALDH1A1TSHR
SCHEMBL17320454 0.83 NR1H2 (0.51) NR1H2DDR1MELKCSF1RYES1
SCHEMBL25531032 0.82 NR1H2 (0.48) NR1H2KDM4EALDH1A1ATMPOLB
SCHEMBL9609585 0.82 NR1H2 (0.54) NR1H2DDR1ABL1KDM4EALDH1A1
SCHEMBL20706218 0.82 DDR1 (0.42) NR1H2DDR1MELKCSF1RYES1
SCHEMBL1782464 0.81 GPR183 (0.52) NR1H2DDR1MELKMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10196378-B2 Inhibitors of BCR-ABL mutants and use thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-02-05 US disclosed
US-20180057479-A1 Inhibitors of BCR-ABL Mutants and Use Thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2018-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180057479-A1 Inhibitors of BCR-ABL Mutants and Use Thereof ABL1, BCR, ABL2 NR1H2 3982/4885DDR1 1969/4885MELK 708/4885
US-10196378-B2 Inhibitors of BCR-ABL mutants and use thereof ABL1, BCR, ABL2 NR1H2 3982/4885DDR1 1969/4885MELK 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.